Announcement:
Top line data for Oraglutide long acting oral GLP1 in proof of Concept IVGTT Clinical Study - Pending. Details embargoed
January 12, 2010
Publication
Clamp study showing increased glucose infusion rate while maintaining low insulinlevels in outer blood circulation. After ten day treatment follow-up, significantreductions in weight, HbA1c and triglycerides observed.
Read More
2024
Press Release
Read More
December 24, 2020
Publication
General review of peptide delivery, describing different mechanisms exploited, and technologies in development for a range of peptides.
Read More
December 9, 2022
Publication
Report of Diabetology's dose-ranging phase 2b study with 100 patients. Significant falls in HbA1c, FPG and triglycerides. No adverse effects. No reports of hypoglycaemia in 25,000 dosing events.
Read More
November 6, 2024
Publication
Results of preclinical studies with exenatide, semaglutide and other GLP-1 analogues in rodents and large animals. Description of mechanism of action of Diabetology' Axcess technology used in Capsulin.
Read More
11/04/2023
Publication
Explanation of the way in which oral insulin differs from injected, and the many advantages of oral over injected insulin
Read More
July 5, 2025
Press Release
Read More
NOvember 11, 2025
Publication
Overview of the development of oral insulin up to the present time, and demonstration of its readiness for commercialisation
Read More
April 04, 2004
Publication
First demonstration of glucose falls in T1DM with Diabetology's Capsulin
Read More
Oral Capsule Technology for Insulin, GLP-1 and Other Protein-Based Therapies and Combinations.
Copyright © 2026 Diabetology Ltd. All rights reserved.
